Pompe Disease — Deal Benchmarks & Valuation
Market Analysis
Pompe Disease is one of the most actively transacted indications in metabolic licensing. Phase 1 deals for pompe disease carry a median total deal value of $2.0B, with upfront payments ranging from $116M to $383M. The recommended deal structure allocates approximately 13% to upfront payments and 87% to milestones.
Milestone structures for pompe disease deals allocate $514M to development milestones, $428M to regulatory milestones, and $771M to commercial milestones. Royalty rates range from 9.5% to 17.8% at the base tier, with tiered escalation reaching 13.5%-21.8% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for pompe disease licensing?
What royalty rates are standard for pompe disease deals?
How are pompe disease deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.